This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quarmby, V. Articles by Canova-Davis, E. Search for Related Content PubMed PubMed Citation Articles by Quarmby, V. Articles by Canova-Davis, E.

How Much Insulin-Like Growth Factor I (IGF-I) Circulates? Impact of Standardization on IGF-I Assay Accuracy

Departments of Bioanalytical Technology (V.Q.), Biostatistics (P.C.), and Analytical Chemistry (C.Q., V.L., E.C.D.), Genentech, Inc., South San Francisco, California 94080

Address all correspondence and requests for reprints to: Dr. V. Quarmby, Bioanalytical Technology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080.

Abstract

There is a significant systematic difference between the normal range obtained from ethylenediamine tetraacetate plasma samples using the Genentech total insulin-like growth factor I (IGF-I) RIA and normal ranges for other total IGF-I RIAs. To determine whether the quality of the assay standard was the cause of this systematic difference, we analyzed commercially available preparations of recombinant human IGF-I (rhIGF-I) typical of those used as IGF-I immunoassay standards along with our own well characterized rhIGF-I assay standard. For the commercial standards, high performance liquid chromatography-derived purities were low, and some vendor-assigned protein concentrations were inconsistent with values from quantitative amino acid analysis. The Genentech rhIGF-I assay standard was highly pure and quantitatively correct. However, the poor quality of some commercial rhIGF-I preparations was not the primary reason for the systematic discrepancy between the Genentech total IGF-I RIA normal range and most other normal ranges.

Most assays for total IGF-I are calibrated against the WHO International Reference Reagent (IRR) for IGF-I Immunoassays (87/518). The Genentech total IGF-I RIA is not calibrated against WHO IRR 87/518. The protein content assigned to WHO IRR 87/518 was a consensus value from a multicenter collaborative study. Physico-chemical analyses showed that WHO IRR 87/518 is Met^-1-IGF-I of low purity (44%), and that the assigned protein content is higher than the value determined by quantitative amino acid analysis. Thus, assays that are calibrated against WHO IRR 87/518 will report total IGF-I concentrations in excess of actual values. We believe that calibration against WHO IRR 87/518 is the cause of the systematic discrepancy between the Genentech IGF-I assay normal range and most other normal ranges, and that much of the plasma IGF-I concentration data in the literature are of questionable accuracy.

This article has been cited by other articles:

				B. P Hauffa, N. Lehmann, M. Bettendorf, O. Mehls, H.-G. Dorr, N. Stahnke, H. Steinkamp, E. Said, M. B Ranke, and participating members of the German KIGS Board/Med Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measured at local treatment centers in growth-impaired children: implications for the agreement between outpatient screening and the results of somatotropic axis functional testing Eur. J. Endocrinol., November 1, 2007; 157(5): 597 - 603. [Abstract] [Full Text] [PDF]

				G. E. Wieringa and P. J. Trainer Harmonizing Growth Hormone Measurements: Learning Lessons for the Future J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2874 - 2875. [Full Text] [PDF]

				N. Mauras, V. Quarmby, and D. C. Bloedow Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins Am J Physiol Endocrinol Metab, October 1, 1999; 277(4): E579 - E584. [Abstract] [Full Text] [PDF]